RxDoctor Payments Data

Shadi Nijim, MD

Nephrology · Las Vegas, NVNPI 1942363791

Payments from drug & device makers

$1,719in general payments, 2019–2025

Across 60 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$442
  • Amgen$176
  • Calliditas Therapeutics US Inc.$152
  • Sanofi-aventis U.S. LLC$145
  • Veloxis Pharmaceuticals, Inc.$117
  • Otsuka America Pharmaceutical, Inc.$114
  • plus $573 from 11 others

What the payments were for

  • Travel & lodging$322%
  • Food & beverage$1,53089%
  • Education$1569%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,719 in reported general payments places this provider in the 45th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada

Medicare billing

Part B allowed, 2024
$265,255
Medicare patients
378
Services billed
2,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cinacalcet Hcl56$7,869
TradjentaLinagliptin12$6,294
Valganciclovir Hcl24$6,252
Mycophenolic AcidMycophenolate Sodium14$5,629
Tacrolimus40$2,579
Mycophenolate Mofetil24$2,093
Novolog FlexpenInsulin Aspart11$1,463
Nifedipine ErNifedipine66$1,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,077
Prednisone137$1,029
Fluconazole33$1,019
Hydralazine Hcl36$490
Famotidine50$365
Tamsulosin Hcl43$338
Carvedilol46$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta$68$6,29412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 125 nephrology providers in Nevada.

Other nephrology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →